Literature DB >> 24565720

Omalizumab mitigates anaphylaxis during ultrarush honey bee venom immunotherapy in monoclonal mast cell activation syndrome.

Elizabeth Nicole da Silva1, Katrina Louise Randall2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24565720     DOI： 10.1016/j.jaip.2013.07.004

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


× No keyword cloud information.
  10 in total

Review 1.  Off-Label Uses of Omalizumab.

Authors:  David El-Qutob
Journal:  Clin Rev Allergy Immunol       Date:  2016-02       Impact factor: 8.667

Review 2.  The Role of KIT Mutations in Anaphylaxis.

Authors:  Elise Coulson; Sherry Zhou; Cem Akin
Journal:  Curr Allergy Asthma Rep       Date:  2019-04-26       Impact factor: 4.806

3.  [Intolerance of specific immunotherapy with Hymenoptera venom: jumping the hurdle with omalizumab].

Authors:  D Wieczorek; A Kapp; B Wedi
Journal:  Hautarzt       Date:  2014-09       Impact factor: 0.751

4.  Omalizumab: A useful tool for inducing tolerance to bee venom immunotherapy.

Authors:  L Ricciardi
Journal:  Int J Immunopathol Pharmacol       Date:  2016-09-27       Impact factor: 3.219

5.  Omalizumab ensures compatibility to bee venom immunotherapy (VIT) after VIT-induced anaphylaxis in a patient with systemic mastocytosis.

Authors:  Askin Gülsen; Franziska Ruëff; Uta Jappe
Journal:  Allergol Select       Date:  2021-03-11

Review 6.  Insights in Anaphylaxis and Clonal Mast Cell Disorders.

Authors:  David González-de-Olano; Iván Álvarez-Twose
Journal:  Front Immunol       Date:  2017-07-10       Impact factor: 7.561

Review 7.  Allergen-specific immunotherapy of Hymenoptera venom allergy - also a matter of diagnosis.

Authors:  Maximilian Schiener; Anke Graessel; Markus Ollert; Carsten B Schmidt-Weber; Simon Blank
Journal:  Hum Vaccin Immunother       Date:  2017-06-12       Impact factor: 3.452

Review 8.  Human(ized) monoclonal antibodies in atopic patients - state of the art.

Authors:  Arzu Didem Yalcin; Kevser Onbasi; Rusen Uzun; Felix Herth; Philipp Albert Schnabel
Journal:  Cent Eur J Immunol       Date:  2020-07-27       Impact factor: 2.085

Review 9.  Mast Cell Activation Syndromes: Collegium Internationale Allergologicum Update 2022.

Authors:  Peter Valent; Karin Hartmann; Patrizia Bonadonna; Marek Niedoszytko; Massimo Triggiani; Michel Arock; Knut Brockow
Journal:  Int Arch Allergy Immunol       Date:  2022-05-23       Impact factor: 3.767

Review 10.  Precision Medicine in Hymenoptera Venom Allergy: Diagnostics, Biomarkers, and Therapy of Different Endotypes and Phenotypes.

Authors:  Simon Blank; Johannes Grosch; Markus Ollert; Maria Beatrice Bilò
Journal:  Front Immunol       Date:  2020-10-22       Impact factor: 7.561
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.